Oxford Bioscience Partners
Overview
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. While willing to consider an investment in a company at almost any stage, OBP primarily works with early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide.
Investment Focus
- Innovative life sciences technologies
- Strong management teams
- Scalable business models
- Potential for significant market impact
- Alignment with Oxford Bioscience Partners' strategic focus areas
Portfolio Companies
Reach Oxford Bioscience Partners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Oxford Bioscience Partners
What sectors does Oxford Bioscience Partners invest in?
Oxford Bioscience Partners invests in Healthcare, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Boston, Massachusetts, United States. Oxford Bioscience Partners is listed as a vc in the ConnectSafely investor database.
What stage does Oxford Bioscience Partners invest at?
Oxford Bioscience Partners backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage.
Which regions does Oxford Bioscience Partners invest in?
Oxford Bioscience Partners invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
What companies has Oxford Bioscience Partners invested in?
Oxford Bioscience Partners's portfolio includes Alnylam Pharmaceuticals, Gilead Sciences, Aegerion Pharmaceuticals, Aptalis Pharma, AstraZeneca, GlaxoSmithKline, ImmunoGen and Ipsen.
How do I contact Oxford Bioscience Partners?
Oxford Bioscience Partners's contact details — including phone — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
